Semler Scientific, Inc. appointed Dr. Murphy-Chutorian as new CEO

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.



On March 19, 2023, Douglas Murphy-Chutorian notified Semler that he intended to resign as chief executive officer in the near term but that he will remain an employee for a period of time to assist with the transition. In connection with his resignation, Semler anticipates that it will enter into a separation agreement to provide for certain severance and other termination benefits in recognition of his years of service and contributions to Semler.



In light of Dr. Murphy-Chutorian's notification, on March 21, 2023, Semler's board of directors appointed Wayne T. Pan, M.D., Ph.D., and current member of the board, as Semler's chief executive officer and president, effective April 3, 2023.

Wayne T. Pan, M.D., Ph.D., age [59], has served as a member of our board of directors since May 2014 and was appointed as chief executive officer in March 2023. Dr. Pan has over 20 years of broad healthcare industry experience from clinical medicine, to managed care, health information technology and biotechnology. Prior to his appointment as chief executive officer, from May 2022 through March 2023, Dr. Pan served as medical director at Banner Health, Insurance Division, responsible for all of Banner's Medicare Programs, including HMO, PPO and D-SNP. Prior to Banner, from June 2021 to May 2022, he was co-founder and chief medical officer of Salusive, Inc., a technology-enabled healthcare services company, based in Emeryville, CA, providing chronic care management and remote patient monitoring services to help physicians manage older adults with chronic conditions, leveraging a proprietary NLP/AI platform that enhances the effectiveness of clinical coaches in real-time as they connect with their patients. From May 2018 to June 2021, he was employed by BioMarin Pharmaceutical Inc., a biotechnology company based in Novato, CA, initially as a medical director in Global Medical Affairs, functioning as the Global Medical Lead for products in development and marketed products treating the mucopolysaccharidoses (MPS) diseases, Morquio A (MPS IVA), Maroteaux-Lamy (MPS VI) and Sanfilippo B (MPS IIIB) syndromes. In January 2021 he moved to the Product Portfolio Development organization as a director, core team leader supporting the PKU gene therapy program. He is also a part-time medical director at San Francisco Health Plan, since May 2014, responsible for utilization management, appeals and grievances and quality improvement programs. From April 2016 to February 2018, he was a medical director in Quality of Care and Health Economics and Outcomes Research, US Medical Affairs at Genentech, Inc., a biotechnology company based in South San Francisco. Earlier in his career, Dr. Pan was a practicing fellowship-trained orthopaedic hand surgeon, a CMO at several regional Medicaid/Medicare Advantage health plans, and CMO of medical groups in the San Francisco Bay Area. Dr. Pan holds an M.B.A. from The Wharton School, University of Pennsylvania and an M.D. and Ph.D. from the Mt. Sinai School of Medicine, and a B.S. in Biology from Johns Hopkins University. 

In connection with his expected appointment as president and chief executive officer, Semler and Dr. Pan expect to enter into an employment agreement providing for compensation and benefits consistent with his new role, which Semler will disclose once finalized. As a current director, Dr. Pan is party to Semler's standard form indemnification agreement. There are no family relationships between Dr. Pan and any member of Semler's board of directors or executive officers.